174 related articles for article (PubMed ID: 19701534)
41. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
Kitoh T; Ohara T; Muto T; Okumura A; Baba R; Koizumi Y; Yamagishi Y; Mikamo H; Daigo K; Hamakubo T
Front Immunol; 2021; 12():624802. PubMed ID: 33912155
[TBL] [Abstract][Full Text] [Related]
42. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
43. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Newburger JW; Sleeper LA; McCrindle BW; Minich LL; Gersony W; Vetter VL; Atz AM; Li JS; Takahashi M; Baker AL; Colan SD; Mitchell PD; Klein GL; Sundel RP;
N Engl J Med; 2007 Feb; 356(7):663-75. PubMed ID: 17301297
[TBL] [Abstract][Full Text] [Related]
44. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events.
Miura M; Kobayashi T; Kaneko T; Ayusawa M; Fukazawa R; Fukushima N; Fuse S; Hamaoka K; Hirono K; Kato T; Mitani Y; Sato S; Shimoyama S; Shiono J; Suda K; Suzuki H; Maeda J; Waki K; ; Kato H; Saji T; Yamagishi H; Ozeki A; Tomotsune M; Yoshida M; Akazawa Y; Aso K; Doi S; Fukasawa Y; Furuno K; Hayabuchi Y; Hayashi M; Honda T; Horita N; Ikeda K; Ishii M; Iwashima S; Kamada M; Kaneko M; Katyama H; Kawamura Y; Kitagawa A; Komori A; Kuraishi K; Masuda H; Matsuda S; Matsuzaki S; Mii S; Miyamoto T; Moritou Y; Motoki N; Nagumo K; Nakamura T; Nishihara E; Nomura Y; Ogata S; Ohashi H; Okumura K; Omori D; Sano T; Suganuma E; Takahashi T; Takatsuki S; Takeda A; Terai M; Toyono M; Watanabe K; Watanabe M; Yamamoto M; Yamamura K
JAMA Pediatr; 2018 May; 172(5):e180030. PubMed ID: 29507955
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
46. Rare refractory Kawasaki disease in an adolescent boy with cardiac and diffuse coronary artery involvement.
Šileikienė R; Kudzytė J; Jankauskas A; Labanauskas L; Rakauskienė V; Jurkienė N; Kėvalas R
Medicina (Kaunas); 2013; 49(7):341-5. PubMed ID: 24375247
[TBL] [Abstract][Full Text] [Related]
47. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
Amarilyo G; Koren Y; Brik Simon D; Bar-Meir M; Bahat H; Helou MH; Mendelson A; Hezkelo N; Chodick G; Berkun Y; Eisenstein E; Butbul Aviel Y; Barkai G; Bolkier Y; Padeh S; Brik R; Hashkes PJ; Harel L; Uziel Y
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):209-212. PubMed ID: 28079513
[TBL] [Abstract][Full Text] [Related]
48. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
49. ATYPICAL KAWASAKI DISEASE.
Ristovski L; Milankov O; Vislavski M; Savić R; Bjelica M
Med Pregl; 2016; 69(1-2):53-7. PubMed ID: 27498535
[TBL] [Abstract][Full Text] [Related]
50. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
Downie ML; Manlhiot C; Collins TH; Chahal N; Yeung RSM; McCrindle BW
Int J Cardiol; 2017 Jun; 236():157-161. PubMed ID: 28089146
[TBL] [Abstract][Full Text] [Related]
51. Corticosteroids in the treatment of the acute phase of Kawasaki disease.
Shinohara M; Sone K; Tomomasa T; Morikawa A
J Pediatr; 1999 Oct; 135(4):465-9. PubMed ID: 10518080
[TBL] [Abstract][Full Text] [Related]
52. Initial intravenous gammaglobulin treatment failure in Kawasaki disease.
Wallace CA; French JW; Kahn SJ; Sherry DD
Pediatrics; 2000 Jun; 105(6):E78. PubMed ID: 10835091
[TBL] [Abstract][Full Text] [Related]
53. [Kawasaki disease in children--9 years experience].
Kowalczyk M; Kawalec W; Daszkowska-York J; Turska-Kmieć A; Brzezińska-Rajszys G; Sobielarska D; Ziółkowska L; Kościesza A; Jagiełłowicz D; Mirecka-Rola A
Med Wieku Rozwoj; 2005; 9(2):179-93. PubMed ID: 16085959
[TBL] [Abstract][Full Text] [Related]
54. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
Tajima M; Shiozawa Y; Kagawa J
Pediatr Cardiol; 2015 Aug; 36(6):1159-65. PubMed ID: 25753685
[TBL] [Abstract][Full Text] [Related]
55. Predicting IVIG resistance in UK Kawasaki disease.
Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
[TBL] [Abstract][Full Text] [Related]
56. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
[TBL] [Abstract][Full Text] [Related]
57. Intravenous Immunoglobulin for the Treatment of Kawasaki Disease.
Shulman ST
Pediatr Ann; 2017 Jan; 46(1):e25-e28. PubMed ID: 28079915
[TBL] [Abstract][Full Text] [Related]
58. Kawasaki Disease.
Newburger JW; Takahashi M; Burns JC
J Am Coll Cardiol; 2016 Apr; 67(14):1738-49. PubMed ID: 27056781
[TBL] [Abstract][Full Text] [Related]
59. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
[TBL] [Abstract][Full Text] [Related]
60. Kawasaki disease patients with six principal symptoms have a high risk of being a non-responder.
Nomura Y; Arata M; Masuda K; Koriyama C; Suruki N; Ueno K; Yoshikawa H; Eguchi T; Kawano Y
Pediatr Int; 2012 Feb; 54(1):14-8. PubMed ID: 22115193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
